1. Home
  2. PRQR vs NCZ Comparison

PRQR vs NCZ Comparison

Compare PRQR & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRQR
  • NCZ
  • Stock Information
  • Founded
  • PRQR 2012
  • NCZ 2003
  • Country
  • PRQR Netherlands
  • NCZ United States
  • Employees
  • PRQR N/A
  • NCZ N/A
  • Industry
  • PRQR Biotechnology: Pharmaceutical Preparations
  • NCZ Finance Companies
  • Sector
  • PRQR Health Care
  • NCZ Finance
  • Exchange
  • PRQR Nasdaq
  • NCZ Nasdaq
  • Market Cap
  • PRQR 224.4M
  • NCZ 228.3M
  • IPO Year
  • PRQR 2014
  • NCZ N/A
  • Fundamental
  • Price
  • PRQR $2.36
  • NCZ $14.17
  • Analyst Decision
  • PRQR Strong Buy
  • NCZ
  • Analyst Count
  • PRQR 8
  • NCZ 0
  • Target Price
  • PRQR $8.88
  • NCZ N/A
  • AVG Volume (30 Days)
  • PRQR 403.1K
  • NCZ 533.0K
  • Earning Date
  • PRQR 11-06-2025
  • NCZ 01-01-0001
  • Dividend Yield
  • PRQR N/A
  • NCZ 12.16%
  • EPS Growth
  • PRQR N/A
  • NCZ N/A
  • EPS
  • PRQR N/A
  • NCZ N/A
  • Revenue
  • PRQR $20,129,184.00
  • NCZ N/A
  • Revenue This Year
  • PRQR N/A
  • NCZ N/A
  • Revenue Next Year
  • PRQR N/A
  • NCZ N/A
  • P/E Ratio
  • PRQR N/A
  • NCZ N/A
  • Revenue Growth
  • PRQR 8.65
  • NCZ N/A
  • 52 Week Low
  • PRQR $1.07
  • NCZ $2.50
  • 52 Week High
  • PRQR $4.62
  • NCZ $3.15
  • Technical
  • Relative Strength Index (RSI)
  • PRQR 57.39
  • NCZ 60.60
  • Support Level
  • PRQR $2.25
  • NCZ $13.76
  • Resistance Level
  • PRQR $2.54
  • NCZ $13.97
  • Average True Range (ATR)
  • PRQR 0.13
  • NCZ 0.18
  • MACD
  • PRQR 0.02
  • NCZ -0.02
  • Stochastic Oscillator
  • PRQR 70.31
  • NCZ 55.38

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

About NCZ Virtus Convertible & Income Fund II of Beneficial Interest

Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.

Share on Social Networks: